Latest news from ENA

ENA presentation webcasts

View ENA presentation webcasts here

Friday 2 December

Advanced soft tissue sarcomas respond to a combination of a new and an existing anti-cancer drug

Munich, Germany: Researchers working to find effective treatments for soft tissue sarcomas have discovered that combining a new anti-cancer drug with an existing one kills cancer cells not only in the laboratory but also in the first two patients treated with it, leading to unusually long-lasting periods without the disease progressing.

Read more

Phase I trial shows that a drug that inhibits the Notch signalling process is active in a range of advanced cancers

Munich, Germany: A new anti-cancer drug that inhibits a key cell signalling process involved in many different cancers has shown that it is capable of stopping the progression of cancer and shrinking tumours. Importantly, it has been able to do this in rare cancers that are less well-studied such as adenoid cystic carcinoma.

Read more

Thursday 1 December

How highs and lows in testosterone levels ‘shock’ prostate cancer cells to death

Munich, Germany: A strategy of alternately flooding and starving the body of testosterone is producing good results in patients who have metastatic prostate cancer that is resistant to treatment by chemical or surgical castration, according to new findings.

Read more

Promising results from new drug combination in patients with advanced solid tumours

Munich, Germany: An experimental drug called TAS-114, which has the potential to increase the anti-cancer effects of chemotherapy without increasing adverse side effects, has shown promising results in patients with hard-to-treat cancers in a phase I clinical trial.

Read more

Revolution in our understanding of cancer’ sees dramatic responses to targeted treatments in advanced cancers
Results from three ground-breaking studies show early benefit to patients

Munich, Germany: The “revolution in the understanding of cancer at the molecular level” has led to dramatic responses in cancer patients to new therapies that are targeted precisely at their particular type of tumours, according to an expert.

Read more

Wednesday 30 November

Anti-cancer drug, CB-839, in combination with everolimus, stops tumours growing in patients with advanced kidney cancer

Munich, Germany: The first drug to target a key enzyme that cancer cells need to keep them alive has shown that it is effective in controlling disease in patients with advanced kidney cancer when it is used in combination with another anti-cancer drug, everolimus.

Read more

Tuesday 29 November

Make funding for cancer research a global priority, say European and US organisations

Munich, Germany: The European Organisation for Research and Treatment of Cancer (EORTC) and the American Association for Cancer Research (AACR) are calling on policymakers and leaders throughout the world to provide robust and sustained funding for cancer research.

Read more

Find us

Avenue Emmanuel Mounier, 83/11
Brussels 1200

Contact us

Follow us